GO
Loading...

Gilead Sciences Inc

More

  • Early Glance: Biotechnology companies Thursday, 15 Jan 2015 | 11:00 AM ET

    Amgen Inc. fell $1.45 or. 9 percent, to $153.71. Biogen Idec fell $4.30 or 1.2 percent, to $344.45. Celgene Corp. fell $1.82 or 1.5 percent, to $119.28.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • Final Glance: Biotechnology companies Wednesday, 14 Jan 2015 | 6:07 PM ET

    Amgen Inc. rose$. 02 or percent, to $155.16. Biogen Idec fell $3.99 or 1.1 percent, to $348.75. Celgene Corp. rose $1.12 or. 9 percent, to $121.10.

  • Midday Glance: Biotechnology companies Wednesday, 14 Jan 2015 | 1:43 PM ET

    Amgen Inc. rose$. 26 or. 2 percent, to $155.40. Biogen Idec fell $1.08 or. 3 percent, to $351.66. Celgene Corp. rose $1.74 or 1.5 percent, to $121.72.

  • Early Glance: Biotechnology companies Wednesday, 14 Jan 2015 | 10:41 AM ET

    Amgen Inc. fell$. 01 or percent, to $155.13. Biogen Idec rose $1.21 or. 3 percent, to $353.95. Celgene Corp. rose$. 61 or. 5 percent, to $120.59.

  • Investors are watching closely to see how insurers decide to cover these drugs, which cost tens of thousands of dollars per treatment, after AbbVie Inc started a competitor to Gilead Sciences' breakthrough hepatitis C treatment. Express Scripts, the largest pharmacy benefit manager in the United States, dropped Gilead Sciences hepatitis C drugs from its main...

  • Final Glance: Biotechnology companies Tuesday, 13 Jan 2015 | 6:15 PM ET

    Amgen Inc. fell $1.08 or. 7 percent, to $155.14. Biogen Idec rose $4.90 or 1.4 percent, to $352.74. Celgene Corp. rose $2.98 or 2.5 percent, to $119.98.

  • Cramer's guide to a treacherous trader's market Tuesday, 13 Jan 2015 | 6:14 PM ET

    One minute it's up, the next minute it's down. Jim Cramer gives two important tips for navigating the rough seas of a volatile market.

  • Most active Nasdaq-traded stocks Tuesday, 13 Jan 2015 | 1:17 PM ET

    Apple Inc. rose 1.9 percent to $111.36 with 34,715,400 shares traded. Arena Pharmaceuticals Inc. rose 6.2 percent to $6.00 with 16,629,800 shares traded. Cisco Systems Inc. rose 1.3 percent to $28.41 with 19,030,700 shares traded.

  • Midday Glance: Biotechnology companies Tuesday, 13 Jan 2015 | 1:17 PM ET

    Amgen Inc. rose $1.17 or. 7 percent, to $157.39. Biogen Idec rose $11.03 or 3.2 percent, to $358.87. Celgene Corp. rose $6.08 or 5.2 percent, to $123.08.

  • Early Glance: Biotechnology companies Tuesday, 13 Jan 2015 | 10:42 AM ET

    Amgen Inc. rose $4.48 or 2.9 percent, to $160.70. Biogen Idec rose $6.78 or 1.9 percent, to $354.62. Celgene Corp. rose $4.31 or 3.7 percent, to $121.31.

  • SAN FRANCISCO, Jan 12- Eli Lilly and Co said on Monday that U.S. insurers are increasing pressure on the price of diabetes medications as they switch coverage from certain drugs to others to trim costs. "We've definitely seen increased price competition, more by payers than the companies themselves," Lilly Chief Financial Officer Derica Rice said on Monday in an...

  • 11 ways to play biotech Monday, 12 Jan 2015 | 6:59 PM ET

    Traders on CNBC's "Fast Money" outlined their strongest plays in the ever-volatile biotechnology space.

  • Final Glance: Biotechnology companies Monday, 12 Jan 2015 | 6:35 PM ET

    Amgen Inc. rose$. 49 or. 3 percent, to $156.22. Biogen Idec rose $5.50 or 1.6 percent, to $347.84. Celgene Corp. rose $3.33 or 2.9 percent, to $117.00.

  • Midday Glance: Biotechnology companies Monday, 12 Jan 2015 | 1:23 PM ET

    Amgen Inc. rose$. 95 or. 6 percent, to $156.68. Biogen Idec rose $6.71 or 2.0 percent, to $349.05. Celgene Corp. rose $2.73 or 2.4 percent, to $116.40.

  • Early Glance: Biotechnology companies Monday, 12 Jan 2015 | 10:45 AM ET

    Amgen Inc. rose $1.19 or. 8 percent, to $156.92. Biogen Idec rose $3.66 or 1.1 percent, to $346.00. Celgene Corp. rose $1.88 or 1.7 percent, to $115.55.

  • Shares of Tekmira Pharmaceuticals soared Monday after the Canadian drugmaker said it would buy privately held OnCore Biopharma to form a team focused on developing a hepatitis B cure. Other drugmakers like Gilead Sciences Inc. have developed new treatments for hepatitis C that have been hailed as breakthroughs in curing the liver-destroying virus.

  • Midday movers: Wynn Resorts, Chevron, Crocs & more Friday, 9 Jan 2015 | 1:15 PM ET

    Some of Friday's midday movers:

  • How to play the JPMorgan health conference Friday, 9 Jan 2015 | 11:57 AM ET
    Ariad Pharmaceuticals Medicinal Chemist Nick Bencivenga works in the company's lab.

    History says the best play is to buy biotech stocks the day before the JPMorgan meeting starts and hold until the end.

  • *Bed, Bath& Beyond stumbles after results, outlook. Nonfarm payrolls rose in December, topping Wall Street expectations while November's surprising gain was also revised higher. But the one really puzzling thing is the lack of any wage growth and in fact, wage decline, in December, "said David Kelly, chief global strategist for JPMorgan Funds in New York.